Compare VFF & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VFF | TLSA |
|---|---|---|
| Founded | 1989 | 2013 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 396.2M | 166.7M |
| IPO Year | 2013 | 2017 |
| Metric | VFF | TLSA |
|---|---|---|
| Price | $2.88 | $1.21 |
| Analyst Decision | Buy | |
| Analyst Count | 1 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 997.3K | 93.4K |
| Earning Date | 06-17-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 184.38 | N/A |
| EPS | ★ 0.27 | N/A |
| Revenue | ★ $215,937,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.98 | N/A |
| P/E Ratio | $11.77 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.45 | $0.73 |
| 52 Week High | $4.99 | $2.60 |
| Indicator | VFF | TLSA |
|---|---|---|
| Relative Strength Index (RSI) | 35.41 | 34.50 |
| Support Level | $2.85 | N/A |
| Resistance Level | $3.40 | $1.56 |
| Average True Range (ATR) | 0.18 | 0.10 |
| MACD | -0.04 | -0.01 |
| Stochastic Oscillator | 0.62 | 4.05 |
Village Farms International Inc owns and operates intensive agricultural greenhouse facilities in British Columbia and Texas, where it produces, markets and sells tomatoes, bell peppers and cucumbers. Its wholly owned subsidiary, Pure Sunfarms, is a vertically integrated licensed producer and supplier of cannabis products sold to other licensed providers and provincial governments across Canada and internationally. The Company's wholly owned subsidiary, Balanced Health, develops and sells, cannabidiol (CBD) based products including ingestible, edible and topical applications. The operating segments of the Company are VF Fresh (Produce), Cannabis Canada, Cannabis U.S., Clean Energy, and Leli . The company makes majority of its revenue from the Produce segment.
Tiziana Life Sciences Ltd is a clinical stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, Alzheimer's, and ALS. Its flagship immunotherapeutic candidate, Foralumab (TZLS-401), which is a fully human anti-CD3 monoclonal antibody, is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's and other CNS indications.